4.6 Review

The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals

期刊

BRITISH JOURNAL OF HAEMATOLOGY
卷 148, 期 1, 页码 15-25

出版社

WILEY
DOI: 10.1111/j.1365-2141.2009.07899.x

关键词

thrombocytopenia; lumbar puncture; epidural anaesthesia; spinal anaesthesia; spinal haematoma

向作者/读者索取更多资源

P>Neuraxial anaesthesia is increasingly performed in thrombocytopenic patients at the time of delivery of pregnancy. There is a lack of data regarding the optimum platelet count at which spinal procedures can be safely performed. Reports are often confounded by the presence of other risk factors for spinal haematomata, such as anticoagulants, antiplatelet agents and other acquired or congenital coagulopathies/platelet function defects or rapidly falling platelet counts. In the absence of these additional risk factors, a platelet count of 80 x 109/l is a 'safe' count for placing an epidural or spinal anaesthetic and 40 x 109/l is a 'safe' count for lumbar puncture. It is likely that lower platelet counts may also be safe but there is insufficient published evidence to make recommendations for lower levels at this stage. For patients with platelet counts of 50-80 x 109/l requiring epidural or spinal anaesthesia and patients with a platelet count 20-40 x 109/l requiring a lumbar puncture, an individual decision based on assessment of risks and benefits should be made.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Management of comorbidities in haemophilia

Christine L. Kempton, Michael Makris, Pal Andre Holme

Summary: The introduction of clotting factor concentrates in the early 1970s led to significant improvements in the quality of life and life expectancy of persons with haemophilia (PWH). Unfortunately, the transmission of HIV and hepatitis C virus (HCV) in the 1980s resulted in the loss of these gains. With four decades of PWH unexposed to contaminated factor products and current treatments capable of suppressing and eliminating HIV and HCV, the survival rate is once again increasing, but elderly PWH still face specific comorbidities such as cardiovascular disease and osteoporosis.

HAEMOPHILIA (2021)

Article Hematology

Management of COVID-19-associated coagulopathy in persons with haemophilia

Steven W. Pipe, Radoslaw Kaczmarek, Alok Srivastava, Glenn F. Pierce, Mike Makris, Cedric Hermans

Summary: COVID-19 associated coagulopathy in patients with hemophilia is complex, requiring a balance of antithrombotic and hemostatic treatments. Recommendations include continued hemostatic treatment, intensified prophylaxis with factor concentrates and LMWH based on bleeding risk, and possibly combining emicizumab with factor VIII and LMWH depending on individual patient needs. Dosage escalation of LMWH tailored to thrombosis risk may be considered, but lacks strong evidence support.

HAEMOPHILIA (2021)

Editorial Material Hematology

Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

Radoslaw Kaczmarek, Magdy El Ekiaby, Daniel P. Hart, Cedric Hermans, Mike Makris, Declan Noone, Brian O'Mahony, David Page, Flora Peyvandi, Steven W. Pipe, Thomas Sannie, Uwe Schlenkrich, Mark W. Skinner, Alok Srivastava, Amanda Bok, Glenn F. Pierce

HAEMOPHILIA (2021)

Letter Hematology

Making treatment decisions in hemophilia based on available safety data

Mike Makris, Cedric Hermans

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Article Hematology

Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update

Daniel P. Hart, Jayanthi Alamelu, Neha Bhatnagar, Tina Biss, Peter W. Collins, Georgina Hall, Charles Hay, Ri Liesner, Michael Makris, Mary Mathias, Jayashree Motwani, Ben Palmer, Jeanette Payne, Charles Percy, Michael Richards, Anne Riddell, Kate Talks, Oliver Tunstall, Elizabeth Chalmers

Summary: The International Immune Tolerance Study showed equal efficacy between high and low dose immune tolerance induction regimens in good risk patients, but was stopped early due to excessive bleed rate in the low dose arm. The UKHCDO guideline revision now recommends using emicizumab as a prophylaxis agent for reduced bleeding rates during ITI. This consensus protocol aims to facilitate future evaluation of ITI outcomes in the changing landscape of haemophilia therapeutics and strategies.

HAEMOPHILIA (2021)

Editorial Material Hematology

The 2021 von Willebrand disease guidelines: Clarity and controversy

Mike Makris, Cedric Hermans

HAEMOPHILIA (2022)

Article Hematology

Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study

Paul van der Valk, Michael Makris, Kathelijn Fischer, Robert C. Tait, Pratima Chowdary, Peter W. Collins, Karina Meijer, Lize F. D. van Vulpen, Eveline Mauser-Bunschoten, Roger E. G. Schutgens

Summary: This study compared the incidence of cardiovascular disease (CVD) in individuals with hemophilia to the predicted incidence, and found that the actual incidence was lower than predicted. There was no statistically significant relationship between the severity of hemophilia and the incidence of CVD.

BLOOD ADVANCES (2022)

Article Hematology

Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis

Brian Craven, William Lester, Sara Boyce, Will Thomas, Angela Kanny, Claire Davies, Sue Pavord, Joannes Hermans, Michael Makris, Emily Bart-Smith, Sarah Arnott, Beverley J. Hunt, Pavel Chudakou, Anthony Calvert, Deepak Singh, Marie Scully

Summary: The COVID-19 pandemic has led to the rapid development of vaccines against SARS-CoV-2. Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare but life-threatening complication. This study measured the levels of antibodies, platelets, and D-dimer in a large cohort of patients and examined their relation to relapse. The results showed that most patients remained positive after diagnosis, but the relapse rate was low and did not result in a recurrence of severe clinical symptoms.
Editorial Material Hematology

Second-dose VITT: rare but real

Sue Pavord, Michael Makris

Summary: In the current issue of Blood, Krzywicka et al convincingly demonstrate for the first time that vaccine-induced immune thrombocytopenia and thrombosis (VITT) can occur after a second dose of the AstraZeneca/Oxford ChAdOx1 nCoV-19 vaccine.
Letter Hematology

Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and EHC

Wolfgang Miesbach, Fariba Baghaei, Ana Boban, Pratima Chowdary, Michiel Coppens, Daniel P. Hart, Victor Jimenez-Yuste, Robert Klamroth, Mike Makris, Declan Noone, Flora Peyvandi

HAEMOPHILIA (2022)

Article Hematology

Anti-PF4 testing for vaccine-induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide

Christopher Reilly-Stitt, Ian Jennings, Steve Kitchen, Mike Makris, Piet Meijer, Moniek de Maat, Marie Scully, Tamam Bakchoul, Isobel D. Walker

Summary: This study conducted a collaborative external quality assessment (EQA) exercise to evaluate the performance of different testing methods for the diagnosis of VITT. The results showed that ELISA-based methods have superior sensitivity compared to functional assays.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Article Hematology

Incidence of adult primary immune thrombocytopenia in England-An update

Indraraj Umesh Doobaree, Katherine Conway, Haroon Miah, Atiqa Miah, Michael Makris, Quentin Hill, Nicola Cooper, Charlotte Bradbury, Adrian Newland, Drew Provan, Vickie McDonald

Summary: The study found a rising incidence of primary ITP, with the most significant increases among young women and elderly men. These findings are important for understanding the impact of ITP on patients' lives and healthcare services in England, particularly as 17%-50% of patients may develop chronic ITP and require long-term care.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

Article Hematology

Von Willebrand disease: Gaining a global perspective

Jamie M. M. O'Sullivan, Ellia Tootoonchian, Baiba Ziemele, Michael Makris, Augusto B. B. Federici, Claudia Khayat Djambas, Magdy El Ekiaby, Dawn Rotellini, Robert F. F. Sidonio, Alfonso Iorio, Donna Coffin, Glenn F. F. Pierce, Jeffrey Stonebraker, Paula D. D. James, Michelle Lavin

Summary: Recent guidelines for von Willebrand Disease (VWD) highlighted the challenges in diagnosis and management. Identifying the number of persons with VWD (PwVWD) internationally will help target support to aid diagnosis of PwVWD. Registration rates of PwVWD vary internationally and are influenced by national income status.

HAEMOPHILIA (2023)

Review Hematology

Reported prevalence of von Willebrand disease worldwide in relation to income classification

Jeffrey S. Stonebraker, Alfonso Iorio, Michelle Lavin, Suely M. Rezende, Alok Srivastava, Glenn F. Pierce, Donna Coffin, Ellia Tootoonchian, Michael Makris

Summary: This study analyzed the reported prevalence of von Willebrand disease (VWD) worldwide in relation to income classification. The results showed that the prevalence of VWD was significantly higher in high-income countries compared to other income classifications, and the prevalence was higher in females than males. The detection and diagnosis of type 1 VWD presented challenges in forming a consistent prevalence value across countries and income classifications.

HAEMOPHILIA (2023)

Article Hematology

Association of patient, treatment and disease characteristics with patient-reported outcomes: Results of the ECHO Registry

Charles R. M. Hay, Michael Makris, Midori Shima, Azusa Nagao, Victor Jimenez-Yuste, Mark Skinner, Craig M. Kessler, Sylvia von Mackensen

Summary: This study investigates the associations between patient-reported outcomes (PROs) and patient, treatment, and disease characteristics in people living with haemophilia A (PLWHA). The results show that older age, poorer joint health, and higher body mass index (BMI) adversely affect multiple aspects of participant well-being.

HAEMOPHILIA (2023)

暂无数据